Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 75 publications

The effect of latanoprostene bunod on retinal vessel density in patients with primary open-angle glaucoma.

The effect of latanoprostene bunod on retinal vessel density in patients with primary open-angle glaucoma.

Journal: European journal of ophthalmology
Published: November 14, 2025

Angina Pectoris Following Latanoprostene Bunod 0.024% Administration: A Case Report.

Angina Pectoris Following Latanoprostene Bunod 0.024% Administration: A Case Report.

Journal: Cureus
Published: November 10, 2025

Drugs for open-angle glaucoma.

Drugs for open-angle glaucoma.

Journal: The Medical letter on drugs and therapeutics
Published: April 22, 2025

Corrigendum: Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication.

Corrigendum: Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication.

Journal: Medical gas research
Published: April 18, 2025

Evaluation of corneal and anterior segment alterations following short-term use of topical latanoprostene bunod.

Evaluation of corneal and anterior segment alterations following short-term use of topical latanoprostene bunod.

Journal: International ophthalmology
Published: March 27, 2025

Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review.

Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review.

Journal: Frontiers in ophthalmology
Published: January 02, 2025

Effects of 0.024% latanoprostene bunod on intraocular pressure and pupil diameter in normal cats and cats with congenital glaucoma.

Effects of 0.024% latanoprostene bunod on intraocular pressure and pupil diameter in normal cats and cats with congenital glaucoma.

Journal: Veterinary ophthalmology
Published: September 30, 2024

Latanoprostene Bunod 0.024% Early Experience Program (LEEP): A Canadian Initiative for Open-Angle Glaucoma and Ocular Hypertension.

Latanoprostene Bunod 0.024% Early Experience Program (LEEP): A Canadian Initiative for Open-Angle Glaucoma and Ocular Hypertension.

Journal: Ophthalmology and therapy
Published: September 18, 2024

Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study.

Systemic adverse drug events to topical prostaglandin analogs for treating glaucoma: a retrospective focused pharmacovigilance study.

Journal: BMC ophthalmology
Published: August 31, 2024

Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication.

Latanoprostene bunod: the first nitric oxide-donating antiglaucoma medication.

Journal: Medical gas research
Published: April 01, 2024

One-year experience with latanoprostene bunod ophthalmic solution 0.024% in clinical practice: A retrospective observational study.

One-year experience with latanoprostene bunod ophthalmic solution 0.024% in clinical practice: A retrospective observational study.

Journal: PloS one
Published: February 21, 2024

The Effect of Latanoprostene Bunod 0.024% on Optical Coherence Tomography Angiography in Newly Diagnosed Open Angle Glaucoma.

The Effect of Latanoprostene Bunod 0.024% on Optical Coherence Tomography Angiography in Newly Diagnosed Open Angle Glaucoma.

Journal: Journal of glaucoma
Published: December 27, 2023
Showing 1-12 of 75

Last Updated: 01/07/2026